Source: Annual Congress 2001 - Problems in treatment of TB
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Cicchitto, A. Vaghi, N. Grassi, S. Capato, G. Besozzi, S. De Lorenzo, G. B. Migliori, R. Centis (Garbagnate, Sondalo, Tradate, Italy). Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy. Eur Respir J 2001; 16: Suppl. 31, 2076

Member's Comments

No comment yet.

Related content which might interest you: Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013 Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study Source: Eur Respir J 2006; 28: 980-985 Year: 2006 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Long-term results of multidrug-resistant tuberculosis treatment. Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 When do we extend the treatment of tuberculosis (TB) more than 6 months? Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Multidrug-resistant tuberculosis in UK children: presentation, management and outcome Source: Eur Respir J 2013; 41: 1456-1458 Year: 2013 Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Reducing loss to follow-up during treatment for drug-resistant tuberculosis Source: Eur Respir J, 53 (1) 1802268; 10.1183/13993003.02268-2018 Year: 2019